Competition Intensifies As Access Increases For US Biosimilars
AmerisourceBergen’s Beth McMahon Also Highlights Ranibizumab And Adalimumab Rivals
At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.
You may also be interested in...
Just-in-time education may be preferred, so patients and providers see it as they are making decisions, OTBB Director Sarah Yim says in an interview.
A balanced policy environment that can support biosimilar competition is needed to allow the drugs to flourish in the US, says Amgen’s executive director of marketing and global biosimilars commercial lead Chad Pettit.
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.